Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsEventsSponsored PodcastsSponsored VideosWebcastsWhitepaperseBooks
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Kevin Williams

Advertisement

Articles by Kevin Williams

Kevin Williams, EVP, Chief Strategy Officer, Ledger Run

Site Satisfaction Is the New Competitive Advantage

ByKevin Williams
October 22nd 2025

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site

    2

    The Hidden Risk in Pharma’s AI Rush

    3

    M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics

    4

    FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia

    5

    FDA Pauses Commissioner’s National Priority Voucher Program: Report

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us